Navigation Links
Declining breast cancer incidence in Canada with declining HRT usage
Date:9/23/2010

Breast cancer incidence declined among postmenopausal women in Canada as their use of hormone therapy declined, according to a study published online September 23 in The Journal of the National Cancer Institute.

The Women's Health Initiative (WHI) trial of more than 16,000 postmenopausal women in the United States reported in 2002 that the risks of combined estrogen and progestin hormone replacement therapy outweighed the benefits. As a result, prescriptions for hormone therapy fell dramatically in several countries around the world and so did the incidence of breast cancer.

To determine whether a similar decline of hormone therapy use and breast cancer incidence occurred in Canada, Prithwish De, Ph.D., of the Canadian Cancer Society, and colleagues, analyzed data from various Canadian registries and from a national health survey for women aged 50-69 years. Specifically, the researchers looked at information on prescriptions for hormone replacement therapy, breast cancer incidence, mammography rates, and self-reported use of hormone replacement therapy.

The researchers found that "the nearly 10% drop in invasive breast cancer rates coincided with the decline in use of hormone replacement therapy reported among Canadian women aged 50-69 years." The steepest decline in use occurred between 2002 and 2004, when use dropped from 12.7% to 4.9%. In that same period, breast cancer incidence dropped 9.6% but mammography rates remained stable.

The researchers write that the decline in breast cancer incidence "is likely explained by the concurrent decline in the use of hormone replacement therapy among Canadian women." They also say the drop in hormone therapy use may be partly explained by the media's coverage of results of both the WHI and the Million Women Study in the U.K., both of which showed that breast cancer risk was elevated with the use of combined hormone therapy. In Canada, cancer rates began to increase again in 2005 among women aged 50-69 years, which might be further evidence of a link between hormone therapy and breast cancer, according to the authors.

"Such a rebound might be expected if occult hormone-sensitive tumors were merely slowed by the withdrawal of hormone replacement therapy rather than prevented by it. If so, hormone replacement therapy may be thought to act as a promoter, rather than a cause of breast cancer," they write.

The study's limitations include the fact that data on hormone replacement therapy use was self-reportedand therefore subject to recall biasand that data on frequency or duration of use were not collected. Also, data on receptor status of breast tumors were not collected.

In conclusion, the authors write that "further long-term surveillance studies of trends between hormone replacement therapy and breast cancer incidence can help reconcile the potential population-level associations of these two factors."


'/>"/>

Contact: Kristine Crane
Kristine.Crane@oxfordjournals.org
301-841-1285
Journal of the National Cancer Institute
Source:Eurekalert

Related medicine news :

1. Youth exposure to alcohol ads in magazines declining
2. Preterm Birth Rates Declining, U.S. Report Shows
3. Declining social security benefits keep older men in workforce
4. Rates of Premature Adult Death Declining Worldwide
5. Survey Finds Access to Mammograms Declining for Women Under Age 50
6. Sexual Problems May Arise After Breast Cancer
7. Mammograms Cut Breast Cancer Death Rates, But Only Modestly: Study
8. 70 percent of women likely to experience sexual problems after breast cancer
9. Physical limitations of breast cancer survivors
10. Studies identify complications in women undergoing mastectomy and immediate breast reconstruction
11. Breast Reconstruction After Mastectomy: Now or Later?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... ... 19, 2017 , ... Adolfson & Peterson Construction (AP) continues ... As a leader in healthcare construction, AP has successfully built several well-known medical ... Midwest with Josh now on board. , Josh brings over nine years ...
(Date:7/18/2017)... ... July 18, 2017 , ... CannaKids, a California Cooperative Cooperation that specializes in ... at the WORLDZ Summit, taking place in Hollywood from July 31-August 1, the ... medical cannabis for both pediatric and adult patients, and how the path has led ...
(Date:7/18/2017)... ... ... An inventor from Anacortes, Wash., knows the difficulties and indignity of not being ... I suffer from anxiety and vertigo on top of that," she said, "so I ... meets that need. , This device enables a woman in menopause to cool off ...
(Date:7/17/2017)... , ... July 17, 2017 , ... ... Depression and Its Treatments during Pregnancy , studies take a closer look at ... on a developing baby with one study showing newer medications may be safer ...
(Date:7/17/2017)... (PRWEB) , ... July 17, 2017 , ... ... medical education events, today announced a partnership with the Texas Academy of ... meeting will take place October 20-22, 2017 at the Hyatt Regency Dallas in ...
Breaking Medicine News(10 mins):
(Date:7/13/2017)... Products, a leader in medical product innovation and global patient care, ... hospice patient care. ... Centurion Medical Products ... management and emotional comfort are part of a hospice,s primary mission. ... unneeded emergency department admission due to severe fecal impaction. One of ...
(Date:7/11/2017)... Calif. , July 11, 2017 Zymo Research Corp., also ... service that can quantify biological aging in a precise manner using the ... Steve Horvath , a professor of human genetics and biostatistics at ... Fielding School of Public Health , Zymo Research,s proprietary DNAge ™ ... ...
(Date:7/11/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ... on the development of oral drug delivery systems, announced ... has agreed to schedule an End-of-Phase II meeting with ... its oral insulin capsule ORMD-0801 in the treatment of ... and secondary endpoints by indicating a statistically significant lowering ...
Breaking Medicine Technology: